An FDA perspective on antiarrhythmic drugs in phase II trials.
Lipicky
R
R
Division of Cardio-Renal Drug Products, Food and Drug Administration, Rockville, MD 20852, USA. lipicky@cder.fda.gov
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015982:Bias; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data*; D003627:Data Interpretation, Statistical; D004305:Dose-Response Relationship, Drug; D006801:Humans; D012107:Research Design; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000889:Anti-Arrhythmia Agents